Home > Insider Trading > Filing (0001181431-10-041128)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356857	Trius Therapeutics Inc	TSRX	Pharmaceutical Preparations (2834)	201320630

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Trius Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego CA 92121		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-08-06	1,892,177	$0.00	1,892,177	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2010-08-06	893,395	$4.38	2,785,572	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2010-08-06	830,000	$5.00	3,615,572	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2010-08-06	10,909,092	$0.00	10,909,092	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-08-06	5,363,636	$0.00	5,363,636	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering, each 8.6 shares of the Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of Common Stock, and had no expiration date.
Shares are held by Sofinnova Venture Partners VII, L.P. ("SV VII"). The Reporting Person is a managing general partner of Sofinnova Management VII, LLC, the general partner of Sofinnova Venture Partners VII, L.P. The Reporting Person may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
The Common Stock was acquired upon conversion of a Secured Convertible Promissory Note exempt from the definition of a derivative security and whose conversion ratio did not become fixed until automatic conversion at the time of the closing of the Issuer's initial public offering.
The shares were purchased in the Issuer's initial public offering.